Nivolumab (N) is a novel therapeutic option in NSCLC, with a significant survival gain compared with Docetaxel (D). However, predictive biomarkers are lacking and no strategies have been adopted to date for optimal patients (pts) selection. The presence of systemic inflammation has been correlated with poor outcome in many cancer types. We aimed to evaluate whether there is a correlation between some indicators of inflammation and response in pts treated with N or D.
|Numero di pagine||1|
|Rivista||Annals of Oncology|
|Stato di pubblicazione||Published - 2017|
All Science Journal Classification (ASJC) codes